Sandor, P. | bioRxiv Science

bioRxiv2026

An inflammatory gene set driven epigenetic clock tracks down disease progression and rejuvenation

Chronic, low-level inflammation, characterized by elevated pro-inflammatory programs, including epigenetic changes, in the absence of infection, is a major driver of aging and age-related diseases. On the other side of the spectrum, aging interventions work, at least in part, by decreasing inflammation. However, the molecular connection between epigenetic aging and inflammatory profiles in chronic diseases and rejuvenation has not been established yet. This study aimed to investigate the role of a newly described inflammatory signature gene set (ISig) in aging, previously associated with accelerated aging, in the progression of chronic diseases and rejuvenation. To achieve this, we developed inflammation-derived epigenetic aging clocks using ElasticNet regression models trained on CpG sites from ISig promoter regions. The newly developed inflammation aging clocks were validated on healthy samples and tested for their capacity to detect accelerated aging in diseased samples and rejuvenation during cellular reprogramming. The data demonstrate that the ISig inflammatory clocks accurately predict age, detect rejuvenation, and identify accelerated aging in disease contexts. Furthermore, we have demonstrated that it is possible to use a curated inflammatory gene-set with biological relevance to estimate biological age acceleration. We also developed a web application, the GeneClock Studio (available at https://ilab.sztaki.hu/geneclockstudio/), that allows researchers to apply the inflammatory aging clocks to their own DNA methylation datasets without requiring any programming expertise. Furthermore, the GeneClockStudio supports the training of new aging clocks based on an arbitrarily selected gene set in a similar way as in the case of the ISig inflammatory clocks.

bioinformatics↗

bioRxiv2025

Distinct patterns of de novo coding variants contribute to Tourette Syndrome etiology

Tourette syndrome (TS) is a highly heritable childhood-onset neuropsychiatric disorder characterized by persistent motor and vocal tics. While both common and rare variants contribute to TS susceptibility, the role of rare de novo mutations (DNMs) remains incompletely characterized. Here, we report findings from the largest TS whole-exome sequencing study to date, analyzing 1,466 TS trios alongside 6,714 autism spectrum disorder (ASD) trios and 5,880 unaffected sibling controls from the Simons Simplex Collection (SSC) and SPARK cohorts. Leveraging a trio-based design across these cohorts enabled calibrated assessment of DNM burden while controlling for background mutation rates. We observed a significant exome-wide enrichment of protein-truncating DNMs in TS probands, particularly within genes intolerant to loss-of-function variation (pLI [≥] 0.9), with little contribution from damaging missense variants. Notably, TS probands did not exhibit enrichment in previously implicated ASD or developmental delay (DD) genes, but elsewhere in the genome, suggesting a distinct rare variant architecture. Using a Bayesian statistical framework that integrates both de novo and rare inherited coding variants, we identified three candidate TS risk genes with FDR [≤] 0.05: PPP5C, EXOC1, and GXYLT1. Literature shows that they have prior links to neurodevelopmental and psychiatric disorders. These findings reveal a rare variant burden in TS that is genetically distinguishable from ASD, underscore the importance of loss-of-function mutations in TS risk, and nominate novel candidate genes for future functional investigation.

neuroscience↗